Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 4/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3332513 | 0.94 | CHRNA4 (0.46) | CHRNA4TAS1R3TAS1R1TAS1R2TLR9 | |
| SCHEMBL3333149 | 0.93 | CHRNA4 (0.45) | CHRNA4TAS1R3TAS1R1TAS1R2TLR9 | |
| SCHEMBL3331966 | 0.89 | CHRNA4 (0.51) | CHRNA4TAS1R3TAS1R1TAS1R2TLR9 | |
| SCHEMBL3336279 | 0.89 | CHRNA4 (0.51) | CHRNA4TAS1R3TAS1R1TAS1R2TLR9 | |
| SCHEMBL3340473 | 0.82 | CHRNA4 (0.50) | CHRNA4TAS1R3TAS1R1TAS1R2TLR9 | |
| SCHEMBL3337480 | 0.81 | CHRNA4 (0.49) | CHRNA4TAS1R3TAS1R1TAS1R2TLR9 | |
| SCHEMBL3335227 | 0.81 | CHRNA4 (0.57) | CHRNA4TAS1R3TAS1R1TAS1R2TLR9 | |
| SCHEMBL3335401 | 0.79 | CHRNA4 (0.62) | CHRNA4TAS1R3TAS1R1TAS1R2TLR9 | |
| SCHEMBL3335917 | 0.79 | CHRNA4 (0.55) | CHRNA4TAS1R3TAS1R1TAS1R2TLR9 | |
| SCHEMBL3333553 | 0.78 | CHRNA4 (0.63) | CHRNA4TAS1R3TAS1R1TAS1R2TLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | US | claimed |
| WO-2008112734-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2008-09-18 | — | — | WO | claimed |
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2008112734-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | CHRNA10, CHRNA2, CHRNE | CHRNA4 8/4885TAS1R3 1487/4885TAS1R1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.